Conference Proceedings

Feasibility of implementing a pharmacist-led DPYD gene testing service for patients commencing 5-fluorouracil (5FU) or capecitabine.

Benjamin Lee, Sarah Glewis, Marliese Alexander, Danny Rischin, Prudence A Francis, Michael Jefford, Hui-Li Wong, Jeanne Tie, Michael Michael, Senthil Lingaratnam

Journal of Clinical Oncology | American Society of Clinical Oncology (ASCO) | Published : 2021


e18644 Background: Polymorphisms in the DPYD gene, which encodes for dihydropyrimidine dehydrogenase (DPD), may impair DPD metabolism of fluoropyrimidines (FP) and cause life-threatening toxicities. The European Medicines Agency (EMA) recommend testing for DPD activity before FP therapy, but the Australian Therapeutic Goods Administration and the US Food and Drug Administration do not currently recommend this. At our hospital, pre-emptive DPYD gene screening was established in response to 7 cases of severe FP-toxicity and significant challenges for timely access to the life-saving antidote, uridine triacetate (UT), in the preceding 3 years. This study assessed the feasibility of a pharmacis..

View full abstract